Authorized purpose: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.
Clinical role
Radiotherapy contouring, treatment planning, adaptation, or treatment-session management under professional review.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: The automatic contouring is initial contouring for clinicians and must be confirmed by the radiation oncology department for treatment planning.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: CT images and DICOM objects.
Who uses it?Intended users: Clinicians, the radiation oncology department, and other professions where a segmented mask of organs is needed.
What does the software produce?Output: DICOM-RT structures of contoured objects, with manual contouring available.
What is its most important limitation?Key limitation: The automatic contouring is initial contouring for clinicians and must be confirmed by the radiation oncology department for treatment planning.
Clinical takeaway. Clinical role: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.
Evidence takeaway. Evidence from the reviewed source record: K242994 reports manufacturer software and segmentation-performance validation for the specified structures and regions; radiation-oncology staff must confirm and edit initial contours.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The exact packet states CT images as the contouring input and separately describes receiving, transmitting, storing, retrieving, displaying, and processing medical images and DICOM objects; it does not establish prescriptions, plans, or treatment-session data as inputs.
DICOM-RT structures of contoured objects, with manual contouring available.
Exact FDA submission
Checked 2026-09-19
The exact indication states that the software generates DICOM-RT structures of contoured objects; treatment plans, adapted plans, and session-management outputs are not stated.
Clinicians, the radiation oncology department, and other professions where a segmented mask of organs is needed.
Exact FDA submission
Checked 2026-09-19
The exact indication names clinicians, the radiation oncology department, and other professions; it does not establish the dossier's specific list of radiation-oncology job titles.
K242994 reports manufacturer software and segmentation-performance validation for the specified structures and regions; radiation-oncology staff must confirm and edit initial contours.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K242994 reports manufacturer software and segmentation-performance validation for the specified structures and regions; radiation-oncology staff must confirm and edit initial contours.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K242994 FDA performance package for OncoStudio (OS-01)
DesignManufacturer software verification and segmentation-performance validation
PopulationCT radiotherapy-planning images covering head and neck, thorax, abdomen, and pelvis
Scopeexact submission
Tested versionOncoStudio OS-01
IndependenceSponsor or vendor study
K242994
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242994 by exact submission identifier. This does not exclude product-family or later safety information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT images and DICOM objects.
Scope: Exact FDA submission. The exact packet states CT images as the contouring input and separately describes receiving, transmitting, storing, retrieving, displaying, and processing medical images and DICOM objects; it does not establish prescriptions, plans, or treatment-session data as inputs.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM RT and vendor workflow integration; validate patient identity, image geometry, structures, dose, plan transfer, approvals, version compatibility, and rollback.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: DICOM-RT structures of contoured objects, with manual contouring available.
Scope: Exact FDA submission. The exact indication states that the software generates DICOM-RT structures of contoured objects; treatment plans, adapted plans, and session-management outputs are not stated.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM-RT structures of contoured objects, with manual contouring available.
Scope: Exact FDA submission. The exact indication states that the software generates DICOM-RT structures of contoured objects; treatment plans, adapted plans, and session-management outputs are not stated.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM RT and vendor workflow integration; validate patient identity, image geometry, structures, dose, plan transfer, approvals, version compatibility, and rollback.
Only qualified radiation oncologists, medical physicists, dosimetrists, and radiation therapists. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.
DICOM RT and vendor workflow integration; validate patient identity, image geometry, structures, dose, plan transfer, approvals, version compatibility, and rollback.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Generated or modified contours and plans require qualified review, editing when needed, independent checks, and final approval before treatment.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
7Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 7 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 7 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.
Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.
Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.
Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.